Amprion, a diagnostics company focused on seed‑amplification testing for neurodegenerative disorders, has reached an agreement with Decathlon Capital Partners for a multi‑million‑dollar growth‑funding investment. The financing is structured as customized growth‑debt that offers flexible amortization while remaining non‑dilutive to existing shareholders and preserving management control, giving Amprion additional capital without issuing new equity.
Headquartered in San Diego, Amprion is described as a global leader in advancing diagnosis of conditions such as Parkinson’s disease, Lewy body dementia and Alzheimer’s disease with Lewy body co‑pathology through seed amplification assay (SAA) technology. Its SAAmplify‑αSYN biomarker test (formerly SYNTap) is a first‑in‑class qualitative laboratory developed test and the only seed amplification assay available to aid the diagnosis of synucleinopathies, detecting misfolded α‑synuclein protein—considered a biological hallmark of these disorders. Amprion’s intellectual property around SAA methodology (also referred to as RT‑QuIC or PMCA) extends across research, drug development and commercialization, and the company collaborates with biopharma partners to identify new drug candidates and underlying pathologies.
The new funding from Decathlon will be used to expand Amprion’s diagnostic testing capacity for neurodegenerative diseases, including Parkinson’s, Lewy body dementia and Alzheimer’s with Lewy body variant, supporting both clinical demand and research use. CEO Russ Lebovitz noted that worldwide demand for Amprion’s testing is increasing as clinicians and researchers seek reliable, pathology‑based insights into these disorders, and he emphasized that the tailored financing package provides operational flexibility while preserving Amprion’s governance and ownership structure.
Decathlon Capital Partners specializes in revenue‑based and growth‑debt financing, offering long‑term capital without the dilution and control trade‑offs often associated with equity funding. With offices in Palo Alto and Park City, the firm is active across a wide range of sectors and positions its solutions as an alternative for growth‑stage companies seeking to scale operations or commercialize products while maintaining existing shareholder structures. Managing Director Matt Hoffman framed the Amprion deal as backing a company that addresses a critical need in neurological care through earlier and more accurate diagnosis of neurodegenerative diseases, and said Decathlon is “proud to partner” with Amprion as it scales its testing platform and expands access for physicians and researchers globally.
KEY QUOTES:
“Demand for Amprion’s testing is increasing worldwide as researchers and clinicians recognize the value of reliable, pathology-based insights into Parkinson’s disease, Lewy body dementia and related neurodegenerative disorders. This investment from Decathlon Capital Partners strengthens our ability to meet that demand and accelerate the global adoption of our seed-amplification testing. The tailored financing package provides the operational flexibility needed to support our growth strategy while remaining non-dilutive to existing shareholders and preserving our management control and governance structure.”
Russ Lebovitz, CEO, Amprion
“Amprion is addressing a critical need in neurological care through its commitment to earlier and more accurate diagnosis of neurodegenerative diseases. We are proud to partner with the company as it scales its innovative testing platform and expands access for physicians and researchers worldwide.”
Matt Hoffman, Managing Director, Decathlon Capital Partners
